Clinical effectiveness and safety of TAZ/PIPC (YP-18) 4.5g for the prevention of infectious complication of prostate biopsy

Clinical effectiveness and safety of TAZ/PIPC (YP-18) 4.5g for the prevention of infectious complication of prostate biopsy - Antimicrobial prophylaxis for the infectious complication of the prostate biopsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003228

Enrollment

100

Registered

2010-02-22

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected prostate cancer

Interventions

*TAZ/PIPI (YP-18) 4.5g is administered one or two times on the day of prostate biopsy *Two times which is 30 min before biopsy and after the prostate biopsy (just before discharge or 5hours after t

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patient received prostate biopsy

Exclusion criteria

Exclusion criteria: 1.Patient who has allergy against the TAZ/PIPC or compounds of penicillins 2.Patient who has infectious mononucleosis 3.Others whom doctors in charge considered to be not apropriate

Design outcomes

Primary

Measure	Time frame
Clinical effectiveness and safety of TAZ/PIPC (YP-18) 4.5g for the prevention of infectious complication of prostate biopsy.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026